Kinnate Raises $98m To Take Kinase Inhibitors Into The Clinic
The Series C Round Brings Fundraising Total To $192.5m
The company’s next-generation kinase inhibitors are designed to target unaddressed mutations and overcome treatment resistance. Lead programs focus on BRAF Class II and III mutations and FGFR2/3.
You may also be interested in...
Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.
Biotech hopes this initial approval will be followed by approvals of Pemazyre in bladder cancer, first-line cholangiocarcinoma and possibly even a tumor-agnostic indication for FGFR-mutated cancers.
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.